Cover Image
Market Research Report
Product code 
1046676

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider, By Type, By Process Flow, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Published: | Grand View Research, Inc. | 265 Pages | Delivery time: 2-10 business days

Price

Back to Top
Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider, By Type, By Process Flow, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030
Published: January 11, 2022
Grand View Research, Inc.
Content info: 265 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is expected to reach USD 17.36 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.5% from 2022 to 2030. Increasing incidence of Adverse Drug Reactions (ADRs) is the key growth driver. ADR imposes a substantial burden on healthcare systems and is one of the prominent causes of morbidity in developed countries. According to the National Center for Biotechnology Information (NCBI), approximately 5% of total hospitalizations in Europe each year are due to ADR. Pharmacovigilance services play an integral role in this clinical trial phase by assisting manufacturers in identifying adverse effects associated with the drug.

COVID-19 has undoubtedly thrown up numerous challenges as well as opportunities for pharmacovigilance service providers. Various companies are developing innovative platforms to gain a competitive edge. For instance, in December 2020, ArisGlobal and EVERSANA declared a strategic partnership to digitally transform end-to-end pharmacovigilance services globally.

The community involved in a PV procedure has been quick to respond to the pandemic. Some companies are using big data analytics against COVID-19. Thus, this refers to the in-depth analysis of data from multiple sources. In April 2020, Saama Technologies offered its Life Science Analytics Cloud technology platform to support the consortium creation. The purpose is to fetch data from both current and future studies to slash the time required to discover a treatment by as much as 50%. Life Science Analytics Cloud is an artificial intelligence-powered platform. This represents the scope for future developments in this market.

According to the World Health Organization's (WHO) report on pharmaceutical consumption, chronic disease medications accounted for the larger proportion of the total volume of drug consumption in non-hospital setups. Hence, there has been a significant rise in the number of medicines made available to healthcare consumers. The rising demand for drugs has significantly heightened the need for the development of novel therapeutics via extensive clinical trials, which is expected to serve this market with lucrative opportunities.

Moreover, leading pharma companies in developed countries are focusing on outsourcing PV services to reduce costs and minimize operational expenses. This is anticipated to serve as an opportunity for contact research organizations in developing regions to gain more revenue share. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for pharmacovigilance services during the forecast period.

The companies operating in the market are undertaking strategic initiatives, such as collaborations with the PV service providers, to gain access to medical information and to manage PV workflows. For instance, In October 2021, The Whiteboard, an academy for training specialists in the clinical trials and drug development field, proclaimed a partnership with Oviya MedSafe, a worldwide drug safety service, and pharmacovigilance consulting corporation.

Similarly, in September 2019, Accenture collaborated with Bayer to implement the company's INTIENT Clinical platform to simplify and speed its drug development processes, thereby widening its business. The company collaborated with BioCelebrate in the past to develop a platform for aggregating and analyzing clinical information for improved drug developing efficiency, thus enhancing its R&D capabilities. Such initiatives help companies maintain their position and thereby support market growth.

Pharmacovigilance Market Report Highlights:

  • On the basis of a product life cycle, the phase IV segment held a dominant revenue share of over 75.0% in 2021 owing to the extensive post-marketing surveillance of pharmaceuticals and an increasing number of ADR incidences in the market
  • By service provider, contract outsourcing held a significant revenue share of over 55.0% in 2021 owing to the shift in the focus of pharmaceutical companies to outsourcing services to reduce operational cost
  • Based on type, spontaneous reporting held the largest revenue share in 2021 due to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
  • The biotechnology companies end-use segment is anticipated to exhibit a lucrative CAGR over the forecast period owing to the increasing R&D for the development of novel biologics
  • Asia Pacific is anticipated to expand at the fastest CAGR of 12.1% over the forecast period. This is attributed to the availability of low-cost labor and the rising number of outsourcing companies in this region
  • Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services. Moreover, companies are adopting strategies including new product launches, collaborations, and mergers & acquisitions to gain a competitive advantage
Product Code: 978-1-68038-327-0

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Service Provider
    • 1.1.2 Type
    • 1.1.3 Product Life Cycle
    • 1.1.4 Process Flow
    • 1.1.5 TherapeutiC area
    • 1.1.6 End-use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
      • 1.3.5.1 Data for primary interviews in North America
      • 1.3.5.2 Data for Primary Interviews in Europe
      • 1.3.5.3 Data for Primary Interviews in APAC
      • 1.3.5.4 Data for Primary Interviews in Latin America
      • 1.3.5.5 Data for Primary Interviews in MEA
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Market Definitions
    • 1.9.1 Product Life Cycle
      • 1.9.1.1 Pre-clinical
      • 1.9.1.2 Phase I
      • 1.9.1.3 Phase II
      • 1.9.1.4 Phase III
      • 1.9.1.5 Phase IV
    • 1.9.2 Type of Methods Outlook
      • 1.9.2.1 Spontaneous reporting
      • 1.9.2.2 Intensified ADR Reporting
      • 1.9.2.3 Targeted Spontaneous Reporting
      • 1.9.2.4 Cohort Event Monitoring
      • 1.9.2.5 EHR Mining
    • 1.9.3 Service Providers Outlook
      • 1.9.3.1 In-house
      • 1.9.3.2 Outsourcing
    • 1.9.4 End-use Outlook
      • 1.9.4.1 Pharmaceuticals & Biotechnology Companies
      • 1.9.4.2 Medical Device Manufacturers
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Pharmacovigilance Market Outlook, 2017 - 2030 (USD Million)
  • 2.3 Segment Outlook
  • 2.4 Competitive Outlook

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market analysis
    • 3.1.2 Ancillary market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Growing drug consumption and drug development rates
      • 3.3.1.2 Increasing incidence of ADR and drug toxicity
      • 3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
      • 3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.3.1.5 Increasing Regulatory Burden on Manufacturers
      • 3.3.1.6 Introduction of technologically advanced software services
      • 3.3.1.7 Constantly rising investment in R&D by healthcare companies
      • 3.3.1.8 Partnerships and collaborations between market players
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Shortage of skilled labor
      • 3.3.2.2 Expensive technology for small and mid-sized players
      • 3.3.2.3 Lack of recognition
      • 3.3.2.4 Scarcity of integration standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Pre-clinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle Against Service Offering And Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List of regulatory bodies by Country
  • 3.9 Pharmacovigilance: Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation By Activities
    • 3.10.2 By Development phase
    • 3.10.3 By Therapeutic area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Case processing
      • 3.10.4.2 ADR Reporting
      • 3.10.4.3 Medical writing
      • 3.10.4.4 Drug safety management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature screening
      • 3.11.1.3 Automation and AI
      • 3.11.1.4 Big data analytics in PV

Chapter 4 COVID-19 Impact Analysis

  • 4.1 COVID-19 Outbreak
    • 4.1.1 Challenges for safety reporting activities
  • 4.2 Demand Analysis
    • 4.2.1 Product Pipeline Analysis, by Stage for COVID-19
  • 4.3 Recent Developments & Strategic Outcomes
    • 4.3.1 Regulatory requirements/changes due to covid-19
    • 4.3.2 Strategies implemented by companies
      • 4.3.2.1 IQVIA
      • 4.3.2.2 PARAXEL International Corporation
      • 4.3.2.3 Bioclinica
      • 4.3.2.4 Pharmaceutical Product Development (PPD)
      • 4.3.2.5 IBM Corporation
      • 4.3.2.6 ICON, plc
      • 4.3.2.7 PRA Health Sciences
      • 4.3.2.8 Covance Inc.
      • 4.3.2.9 ArisGlobal
      • 4.3.2.10 Linical Accelovance
      • 4.3.2.11 Laboratory Corporation of America Holdings

Chapter 5 Pharmacovigilance Market: Service provider Estimates & Trend Analysis

  • 5.1 Service Provider Market Share Analysis, 2021 & 2030
  • 5.2 Service Provider Dashboard
    • 5.2.1 In-house
      • 5.2.1.1 In-house market estimates and forecasts, 2017 - 2030 (USD Million)
    • 5.2.2 Contract Outsourcing
      • 5.2.2.1 Contract outsourcing market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2021 & 2030
  • 6.2 Type Dashboard
    • 6.2.1 Spontaneous Reporting
      • 6.2.1.1 Spontaneous Reporting market estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.2.2 Intensified ADR Reporting
      • 6.2.2.1 Intensified ADR Reporting market estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.2.3 Targeted Spontaneous Reporting
      • 6.2.3.1 Targeted spontaneous reporting market estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.2.4 Cohort Event Monitoring (CEM)
      • 6.2.4.1 CEM market estimates and forecasts, 2017 - 2030 (USD Million)
    • 6.2.5 EHR Mining
      • 6.2.5.1 EHR Mining market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 7.1 Product Life Cycle Market Share Analysis, 2021 & 2030
  • 7.2 Product Dashboard
    • 7.2.1 Pre-clinical
      • 7.2.1.1 Pre-clinical market estimates and forecasts, 2017 - 2030 (USD Million)
    • 7.2.2 Phase I
      • 7.2.2.1 Phase I market estimates and forecasts, 2017 - 2030 (USD Million)
    • 7.2.3 Phase II
      • 7.2.3.1 Phase II market estimates and forecasts, 2017 - 2030 (USD Million)
    • 7.2.4 Phase III
      • 7.2.4.1 Phase III market estimates and forecasts, 2017 - 2030 (USD Million)
    • 7.2.5 Phase IV
      • 7.2.5.1 Phase IV market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 8.1 Process Flow Market Share Analysis, 2021 & 2030
  • 8.2 Process Flow Dashboard
    • 8.2.1 Case data management
      • 8.2.1.1 Case data management market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.1.2 Case logging
      • 8.2.1.3 Case logging market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.1.4 Case data analysis
      • 8.2.1.5 Case data analysis market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.1.6 Medical reviewing and reporting
      • 8.2.1.7 Medical reviewing and reporting market estimates and forecasts, 2017 - 2030 (USD Million)
    • 8.2.2 Signal detection
      • 8.2.2.1 Signal detection market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.2.2 Adverse Event Logging
      • 8.2.2.3 Adverse Event Logging market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.2.4 Adverse Event Analysis
      • 8.2.2.5 Adverse Event Analysis market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.2.6 Adverse Event Review & Reporting
      • 8.2.2.7 Adverse Event Review & Reporting market estimates and forecasts, 2017 - 2030 (USD Million)
    • 8.2.3 Risk Management System
      • 8.2.3.1 Risk Management System market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.3.2 Risk Evaluation System
      • 8.2.3.3 Risk Evaluation System market estimates and forecasts, 2017 - 2030 (USD Million)
      • 8.2.3.4 Risk Mitigation System
      • 8.2.3.5 Risk Mitigation System market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 9.1 Therapeutic Area Market Share Analysis, 2021 & 2030
  • 9.2 Therapeutic Area Dashboard
    • 9.2.1 Oncology
      • 9.2.1.1 Oncology market estimates and forecasts, 2017 - 2030 (USD Million)
    • 9.2.2 Neurology
      • 9.2.2.1 Neurology market estimates and forecasts, 2017 - 2030 (USD Million)
    • 9.2.3 Cardiology
      • 9.2.3.1 Cardiology market estimates and forecasts, 2017 - 2030 (USD Million)
    • 9.2.4 Respiratory systems
      • 9.2.4.1 Respiratory systems market estimates and forecasts, 2017 - 2030 (USD Million)
    • 9.2.5 Others
      • 9.2.5.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis

  • 10.1 End-use Market Share Analysis, 2021 & 2030
  • 10.2 End-use Dashboard
    • 10.2.1 Pharmaceuticals
      • 10.2.1.1 Pharmaceuticals market estimates and forecasts, 2017 - 2030 (USD Million)
    • 10.2.2 Biotechnology Companies
      • 10.2.2.1 Biotechnology companies market estimates and forecasts, 2017 - 2030 (USD Million)
    • 10.2.3 Medical Device Manufacturers
      • 10.2.3.1 Medical Device Manufacturers market estimates and forecasts, 2017 - 2030 (USD Million)
    • 10.2.4 Others
      • 10.2.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 11 Pharmacovigilance Market: Regional Estimates & Trend Analysis by Segments

  • 11.1 Regional Market Snapshot
  • 11.2 Market Share Analysis by Country, 2021
    • 11.2.1 North America
      • 11.2.1.1 SWOT Analysis
    • 11.2.2 Europe
      • 11.2.2.1 SWOT Analysis
    • 11.2.3 Asia Pacific
      • 11.2.3.1 SWOT Analysis
    • 11.2.4 Latin America
      • 11.2.4.1 SWOT Analysis
    • 11.2.5 MEA
      • 11.2.5.1 SWOT Analysis
  • 11.3 North America
    • 11.3.1 North America Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.3.2 U.S.
      • 11.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.3.3 Canada
      • 11.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
  • 11.4 Europe
    • 11.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.2 U.K.
      • 11.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.3 Germany
      • 11.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.4 France
      • 11.4.4.1 France Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.5 Italy
      • 11.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.6 Spain
      • 11.4.6.1 Spain pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.4.7 Russia
      • 11.4.7.1 Russia Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
  • 11.5 Asia Pacific
    • 11.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.5.2 Japan
      • 11.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.5.3 China
      • 11.5.3.1 China Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.5.4 India
      • 11.5.4.1 India Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
  • 11.6 Latin America
    • 11.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.6.2 Brazil
      • 11.6.2.1 Brazil Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.6.3 Mexico
      • 11.6.3.1 Mexico Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
  • 11.7 MEA
    • 11.7.1 MEA Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.7.2 South Africa
      • 11.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)
    • 11.7.3 Kingdom of Saudi Arabia
      • 11.7.3.1 Kingdom of Saudi Arabia Pharmacovigilance market estimates and forecasts, 2017 - 2030 (USD Million)

Chapter 12 Competitive Outlook

  • 12.1 Market Participation Categorization
  • 12.2 Public Companies
    • 12.2.1 Company market position analysis
    • 12.2.2 Company Market Share
  • 12.3 Private Companies
    • 12.3.1 List of key emerging companies
  • 12.4 Consolidation Trends
  • 12.5 Potential Customers

Chapter 13 Company Profiles

  • 13.1 Accenture
    • 13.1.1 Company overview
    • 13.1.2 Service benchmarking
    • 13.1.3 Organization structure & Team Composition
      • 13.1.3.1 Team composition
    • 13.1.4 Financial performance
    • 13.1.5 R&D expenditure
    • 13.1.6 Strategic initiatives
    • 13.1.7 SWOT Analysis
  • 13.2 Clinquest Group B.V. (Linical Americas)
    • 13.2.1 Company overview
    • 13.2.2 Service benchmarking
    • 13.2.3 Organization structure & Team Composition
      • 13.2.3.1 Team composition
    • 13.2.4 Financial performance
    • 13.2.5 Strategic initiatives
    • 13.2.6 SWOT Analysis
  • 13.3 IQVIA
    • 13.3.1 Company overview
    • 13.3.2 Service benchmarking
    • 13.3.3 Organization structure & Team Composition
      • 13.3.3.1 Team composition
    • 13.3.4 Financial performance
    • 13.3.5 Strategic initiatives
    • 13.3.6 SWOT Analysis
  • 13.4 Cognizant
    • 13.4.1 Company overview
    • 13.4.2 Service benchmarking
    • 13.4.3 Organization structure & Team Composition
      • 13.4.3.1 Team composition
    • 13.4.4 Financial performance
    • 13.4.5 Strategic initiatives
    • 13.4.6 SWOT Analysis
  • 13.5 Laboratory Corporation of America Holdings
    • 13.5.1 Company overview
    • 13.5.2 Service benchmarking
    • 13.5.3 Organization structure & Team Composition
      • 13.5.3.1 Team composition
    • 13.5.4 Financial performance
    • 13.5.5 Strategic initiatives
    • 13.5.6 SWOT Analysis
  • 13.6 IBM Corporation
    • 13.6.1 Company overview
    • 13.6.2 Service benchmarking
    • 13.6.3 Organization structure & Team Composition
      • 13.6.3.1 Team composition
    • 13.6.4 Financial performance
    • 13.6.5 R&D expenditure
    • 13.6.6 Strategic initiatives
    • 13.6.7 SWOT Analysis
  • 13.7 ArisGlobal
    • 13.7.1 Company overview
    • 13.7.2 Service benchmarking
    • 13.7.3 Organization structure & Team Composition
      • 13.7.3.1 Team composition
    • 13.7.4 Financial performance
    • 13.7.5 Strategic initiatives
    • 13.7.6 SWOT Analysis
  • 13.8 ICON Plc.
    • 13.8.1 Company overview
    • 13.8.2 Service benchmarking
    • 13.8.3 Organization structure & Team Composition
      • 13.8.3.1 Team composition
    • 13.8.4 Financial performance
    • 13.8.5 Strategic initiatives
    • 13.8.6 SWOT Analysis
  • 13.9 Capgemini
    • 13.9.1 Company overview
    • 13.9.2 Service benchmarking
    • 13.9.3 Organization structure & Team Composition
      • 13.9.3.1 Team composition
    • 13.9.4 Financial performance
    • 13.9.5 Strategic initiatives
    • 13.9.6 SWOT Analysis
  • 13.10 ITClinical
    • 13.10.1 Company overview
    • 13.10.2 Service benchmarking
    • 13.10.3 Organization structure & Team Composition
      • 13.10.3.1 Team composition
    • 13.10.4 Financial performance
    • 13.10.5 SWOT Analysis
  • 13.11 TAKE Solutions
    • 13.11.1 Company overview
    • 13.11.2 Service benchmarking
    • 13.11.3 Organization structure & Team Composition
      • 13.11.3.1 Team composition
    • 13.11.4 Financial performance
    • 13.11.5 Strategic initiatives
    • 13.11.6 SWOT Analysis
  • 13.12 PAREXEL International Corporation
    • 13.12.1 Company overview
    • 13.12.2 Service benchmarking
    • 13.12.3 Organization structure & Team Composition
      • 13.12.3.1 Team composition
    • 13.12.4 Financial performance
    • 13.12.5 Strategic initiatives
    • 13.12.6 SWOT Analysis
  • 13.13 BioClinica, Inc.
    • 13.13.1 Company overview
    • 13.13.2 Service benchmarking
    • 13.13.3 Organization structure & Team Composition
      • 13.13.3.1 Team composition
    • 13.13.4 Financial performance
    • 13.13.5 Strategic initiatives
    • 13.13.6 SWOT Analysis
  • 13.14 Wipro Limited
    • 13.14.1 Company overview
    • 13.14.2 Service benchmarking
    • 13.14.3 Organization structure & Team Composition
      • 13.14.3.1 Team composition
    • 13.14.4 Financial performance
    • 13.14.5 R&D expenditure
    • 13.14.6 Strategic initiatives
    • 13.14.7 SWOT Analysis
  • 13.15 UNITED BIOSOURCE CORPORATION
    • 13.15.1 Company overview
    • 13.15.2 Service benchmarking
    • 13.15.3 Organization structure & Team Composition
      • 13.15.3.1 Team composition
    • 13.15.4 Financial performance
    • 13.15.5 Strategic initiatives
    • 13.15.6 SWOT Analysis
  • 13.16 FMD K&L
    • 13.16.1 Company overview
    • 13.16.2 Service benchmarking
    • 13.16.3 Organization structure & Team Composition
      • 13.16.3.1 Team composition
    • 13.16.4 Financial performance
    • 13.16.5 Strategic initiatives
    • 13.16.6 SWOT Analysis

Chapter 14 Winning Strategies

  • 14.1 Key Winning/Scoring Criteria's
    • 14.1.1 By categories
      • 14.1.1.1 Pharmaceuticals
      • 14.1.1.2 Biotech companies
      • 14.1.1.3 Medical device companies
  • 14.2 Key Vendor Selection Factors
    • 14.2.1 By Category
    • 14.2.2 BY Company size
      • 14.2.2.1 KEY TAKEAWAYS

Chapter 15 Switching Cost Analysis

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviation
  • TABLE 3 Types of ADRs
  • TABLE 4 Adverse Drug Events (ADEs) in hospitals
  • TABLE 5 List of regulations, by country
  • TABLE 6 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • TABLE 7 List of Major Deals & Acquisitions
  • TABLE 8 List of pharmacovigilance service providers
  • TABLE 9 North America pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 10 North America pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 11 North America pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 12 North America pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 13 North America pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 14 North America pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 15 U.S. pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 16 U.S. pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 17 U.S. pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 18 U.S. pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 19 U.S. pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 20 U.S. pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 21 Canada pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 22 Canada pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 23 Canada pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 24 Canada pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 25 Canada pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 26 Canada pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 27 Europe pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 28 Europe pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 29 Europe pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 30 Europe pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 31 Europe pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 32 Europe pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 33 U.K. pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 34 U.K. pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 35 U.K. pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 36 U.K. pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 37 U.K. pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 38 U.K. pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 39 Germany pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 40 Germany pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 41 Germany pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 42 Germany pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 43 Germany pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 44 Germany pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 45 France pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 46 France pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 47 France pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 48 France pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 49 France pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 50 France pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 51 Italy pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 52 Italy pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 53 Italy pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 54 Italy pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 55 Italy pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 56 Italy pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 57 Spain pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 58 Spain pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 59 Spain pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 60 Spain pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 61 Spain pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 62 Spain pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 63 Russia pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 64 Russia pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 65 Russia pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 66 Russia pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 67 Russia pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 68 Russia pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 69 Asia Pacific pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 70 Asia Pacific pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 71 Asia Pacific pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 72 Asia Pacific pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 73 Asia Pacific pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 74 Asia Pacific pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 75 Japan pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 76 Japan pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 77 Japan pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 78 Japan pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 79 Japan pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 80 Japan pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 81 China pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 82 China pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 83 China pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 84 China pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 85 China pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 86 China pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 87 India pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 88 India pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 89 India pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 90 India pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 91 India pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 92 India pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 93 Latin America pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 94 Latin America pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 95 Latin America pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 96 Latin America pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 97 Latin America pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 98 Latin America pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 99 Brazil pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 100 Brazil pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 101 Brazil pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 102 Brazil pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 103 Brazil pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 104 Brazil pharmacovigilance market, by end use, 2017- 2030 (USD Million
  • TABLE 105 Mexico pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 106 Mexico pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 107 Mexico pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 108 Mexico pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 109 Mexico pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 110 Mexico pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 111 MEA pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 112 MEA pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 113 MEA pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 114 MEA pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 115 MEA pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 116 MEA pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 117 South Africa pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 118 South Africa pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 119 South Africa pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 120 South Africa pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 121 South Africa pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 122 South Africa pharmacovigilance market, by end use, 2017 - 2030 (USD Million)
  • TABLE 123 KSA pharmacovigilance market, by service provider, 2017 - 2030 (USD Million)
  • TABLE 124 KSA pharmacovigilance market, by product life cycle, 2017 - 2030 (USD Million)
  • TABLE 125 KSA pharmacovigilance market, by type, 2017 - 2030 (USD Million)
  • TABLE 126 KSA pharmacovigilance market, by therapeutic area, 2017 - 2030 (USD Million)
  • TABLE 127 KSA pharmacovigilance market, by process flow, 2017 - 2030 (USD Million)
  • TABLE 128 KSA pharmacovigilance market, by end use, 2017 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Data triangulation techniques
  • FIG. 3 Primary research pattern
  • FIG. 4 Primary interviews in North America
  • FIG. 5 Primary interviews in Europe
  • FIG. 6 Primary interviews in APAC
  • FIG. 7 Primary interviews in Latin America
  • FIG. 8 Primary interviews in MEA
  • FIG. 9 Market research approaches
  • FIG. 10 Value-chain-based sizing & forecasting
  • FIG. 11 QFD modeling for market share assessment
  • FIG. 12 Market formulation & validation
  • FIG. 13 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • FIG. 14 Pharmacovigilance market snapshot
  • FIG. 15 Penetration & growth prospect mapping
  • FIG. 16 Pharmacovigilance market dynamics
  • FIG. 17 Pharmacovigilance market driver impact
  • FIG. 18 Pharmacovigilance market restraint impact
  • FIG. 19 Porter's five force model
  • FIG. 20 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 21 Value Chain - Pharmacovigilance Process
  • FIG. 22 General safety and risk management process
  • FIG. 23 Pharmacovigilance Services
  • FIG. 24 Value Chain Analysis Based on Product Life Cycle Stages
  • FIG. 25 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • FIG. 26 PV department
  • FIG. 27 PV organization structure
  • FIG. 28 Estimated budget allocation of drug safety activities at global and country-level, 2021
  • FIG. 29 Comparison between estimated global and country-level drug safety budget allocation, 2021
  • FIG. 30 Average % of drug safety budget contributed by function at a global level
  • FIG. 31 Clinical trial cost by phase (%)
  • FIG. 32 The average monthly cost of illness due to ADRs
  • FIG. 33 Trending topics on social media
  • FIG. 34 ADR detection and from social media data
  • FIG. 35 Common literature automation tool flow
  • FIG. 36 Automation processes in PV
  • FIG. 37 Deterrents to Leveraging the Cloud (Oracle Survey)
  • FIG. 38 The three-step process to compute signal statistics from search log using big data
  • FIG. 39 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • FIG. 40 Pharmacovigilance market: Service provider movement analysis
  • FIG. 41 Pharmacovigilance Service provider dashboard
  • FIG. 42 Global In-house market, 2017 - 2030 (USD Million)
  • FIG. 43 Global contract outsourcing market, 2017 - 2030 (USD Million)
  • FIG. 44 Pharmacovigilance market: Type movement analysis
  • FIG. 45 Pharmacovigilance type dashboard
  • FIG. 46 Global spontaneous reporting market, 2017 - 2030 (USD Million)
  • FIG. 47 Global intensified ADR reporting market, 2017 - 2030 (USD Million)
  • FIG. 48 Global targeted spontaneous reporting market, 2017 - 2030 (USD Million)
  • FIG. 49 Global CEM market, 2017 - 2030 (USD Million)
  • FIG. 50 Global EHR mining market, 2017 - 2030 (USD Million)
  • FIG. 51 Pharmacovigilance market: Product life cycle movement analysis
  • FIG. 52 Pharmacovigilance market product dashboard
  • FIG. 53 Global Pre-clinical market, 2017 - 2030 (USD Million)
  • FIG. 54 Global Phase I market, 2017 - 2030 (USD Million)
  • FIG. 55 Global Phase II market, 2017 - 2030 (USD Million)
  • FIG. 56 Global Phase III market, 2017 - 2030 (USD Million)
  • FIG. 57 Global Phase IV market, 2017 - 2030 (USD Million)
  • FIG. 58 Pharmacovigilance market: Process flow movement analysis
  • FIG. 59 Pharmacovigilance market process flow dashboard
  • FIG. 60 Global case data management market, 2017 - 2030 (USD Million)
  • FIG. 61 Global case logging market, 2017 - 2030 (USD Million)
  • FIG. 62 Global case data analysis market, 2017 - 2030 (USD Million)
  • FIG. 63 Global medical reviewing and reporting market, 2017 - 2030 (USD Million)
  • FIG. 64 Global signal detection market, 2017 - 2030 (USD Million)
  • FIG. 65 Global adverse event logging market, 2017 - 2030 (USD Million)
  • FIG. 66 Global adverse event analysis market, 2017 - 2030 (USD Million)
  • FIG. 67 Global adverse event review & reporting market, 2017 - 2030 (USD Million)
  • FIG. 68 Global risk management system market, 2017 - 2030 (USD Million)
  • FIG. 69 Global Risk Evaluation System market, 2017 - 2030 (USD Million)
  • FIG. 70 Global risk mitigation system market, 2017 - 2030 (USD Million)
  • FIG. 71 Pharmacovigilance market: Therapeutic area movement analysis
  • FIG. 72 Pharmacovigilance market therapeutic area dashboard
  • FIG. 73 Global oncology market, 2017 - 2030 (USD Million)
  • FIG. 74 Global neurology market, 2017 - 2030 (USD Million)
  • FIG. 75 Global cardiology market, 2017 - 2030 (USD Million)
  • FIG. 76 Global respiratory systems market, 2017 - 2030 (USD Million)
  • FIG. 77 Global others market, 2017 - 2030 (USD Million)
  • FIG. 78 Pharmacovigilance market: End-use movement analysis
  • FIG. 79 Pharmacovigilance market end-use dashboard
  • FIG. 80 Global pharmaceuticals market, 2017 - 2030 (USD Million)
  • FIG. 81 Global biotechnology companies' market, 2017 - 2030 (USD Million)
  • FIG. 82 Global medical device manufacturers market, 2017 - 2030 (USD Million)
  • FIG. 83 Global others market, 2017 - 2030 (USD Million)
  • FIG. 84 Regional market place: Key takeaways
  • FIG. 85 North America pharmacovigilance market share by countries, 2021
  • FIG. 86 Europe pharmacovigilance market share by countries, 2021
  • FIG. 87 Asia Pacific pharmacovigilance market share by countries, 2021
  • FIG. 88 Latin America pharmacovigilance market share by countries, 2021
  • FIG. 89 MEA pharmacovigilance market share by countries, 2021
  • FIG. 90 Regional outlook, 2021 & 2030
  • FIG. 91 North America pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 92 U.S. pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 93 Canada pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 94 Europe pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 95 U.K. pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 96 Germany pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 97 France pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 98 Italy pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 99 Spain pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 100 Russia pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 101 Asia Pacific Pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 102 Japan pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 103 China pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 104 India pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 105 Latin America pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 106 Brazil pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 107 Mexico pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 108 MEA pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 109 South Africa pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 110 Kingdom of Saudi Arabia pharmacovigilance market, 2017 - 2030 (USD Million)
  • FIG. 111 Market participant categorization
  • FIG. 112 Company market position analysis
  • FIG. 113 Estimated company market share analysis, 2021 (%)
  • FIG. 114 Organization Structure - Accenture
  • FIG. 115 SWOT - Accenture
  • FIG. 116 Organization Structure - Linical Americas.
  • FIG. 117 SWOT - Linical Americas
  • FIG. 118 Organization Structure - IQVIA
  • FIG. 119 SWOT - IQVIA
  • FIG. 120 Organization Structure - Cognizant
  • FIG. 121 SWOT - Cognizant
  • FIG. 122 Organization Structure - Laboratory Corporation of America Holdings
  • FIG. 123 SWOT - LABORATORY CORPORATION OF AMERICA HOLDINGS
  • FIG. 124 Organization Structure - IBM
  • FIG. 125 SWOT - IBM
  • FIG. 126 Organization Structure - ArisGlobal
  • FIG. 127 SWOT - ArisGlobal
  • FIG. 128 Organization Structure - ICON Plc
  • FIG. 129 SWOT - ICON Plc
  • FIG. 130 Organization Structure - Capgemini
  • FIG. 131 SWOT - Capgemini
  • FIG. 132 Organization Structure - ITC Clinical
  • FIG. 133 SWOT - ITC Clinical
  • FIG. 134 Organization Structure - Take Solutions
  • FIG. 135 SWOT - Take Solutions
  • FIG. 136 Organization Structure - Paraxel Corporation
  • FIG. 137 SWOT - PARAXEL
  • FIG. 138 Organization Structure - BioClinica, Inc.
  • FIG. 139 SWOT - BioClinica, Inc.
  • FIG. 140 Organization Structure - Wipro Ltd.
  • FIG. 141 SWOT - Wipro Ltd.
  • FIG. 142 Organization Structure - UBC
  • FIG. 143 SWOT - UBC
  • FIG. 144 Organization Structure FMD K&L
  • FIG. 145 SWOT - FMD K&L
  • FIG. 146 Commonly outsourced PV activities
  • FIG. 147 Vendor selection criteria